Histone Deacetylase 10-inhibitor Co-Treatment in Cancer

Histone deacetylase inhibitors (HDACi) are promising anticancer agents and are currently being evaluated in clinical trials. However, due to their unselective action, pan-HDACi exhibit dose-limiting side-effects restricting their full potential in anti-cancer therapy. Therefore, characterization of the molecular function of single HDAC isozymes is of major importance for a targeted therapy with less side-effects. We show that HDAC10 overexpression mediated cell survival and targeting of HDAC10 sensitized tumor cells for cytotoxic drug treatment and it correlates with progression or recurrence of neuroblastoma in vivo. These results demonstrate for the first time that HDAC10 induces an alternative lysosomal-mediated tumor cell death pathway, re-sensitizes cells for cytotoxic drugs and may thus be a novel strategy for neuroblastoma therapy.

Further Information: PDF

Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Innovative 3D printed scaffolds offer new hope for bone healing

Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…

The surprising role of gut infection in Alzheimer’s disease

ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…

Molecular gardening: New enzymes discovered for protein modification pruning

How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…